Clostridium Vaccine Market 2019 Estimated Size, Industry Share, Future Predications, Global Analysis, Competitive Landscape, And Regional Forecast To 2026

Clostridium is a gram-positive bacteria, which includes various human pathogens including causative agents of botulism and tetanus. Clostridium difficile infections are the most widely recognized cause of hospital-acquired infectious diarrhea, which necessitates for development of prevention vaccine for this disease. Clostridium difficile, produces an anaerobic toxin that is transmitted through fecal-oral route. Clostridium difficile infection is caused during antibiotic treatment or due to healthcare-associated infection. It leads to asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation.

Increasing C. difficile infections at healthcare facilities and growing antibiotic resistance to treatment drugs are boosting the demand for development of prophylactic options, in order to reduce the risk of infection in vulnerable patients. A 2013 bulletin published from the Centers for Disease Control and Prevention (CDC) stated that Clostridium difficile is an urgent antibiotic-resistance threats in the U.S.

Get an exclusive sample copy of the business report: https://www.coherentmarketinsights.com/insight/request-sample/2359

Global Clostridium Vaccine Market Dynamics-Drivers

Growing occurrence and high prevalence of clostridium difficile infection is expected to drive growth of the global clostridium vaccine market during the forecast period. According to Centers for Disease Control and Prevention (CDC), in 2015, around 500,000 people in the U.S. suffered from clostridium difficile infection.

Moreover, according to National Center for Biotechnology Information (NCBI), in 2012, around 37,900 patients were suffering from clostridium difficile infection in Canada. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016, reported significant incidence of clostridium difficile infection in China.

However, there is no substitute therapies apart from antibiotics available for the treatment of clostridium difficile infection. In severe cases, the only option available is surgery, fecal microbiota transplant, and probiotics in case of recurrent clostridium difficile infection.

LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2359

Key players in the market are focused on research and development activities for development of clostridium vaccine that can offer preventive measure in the clostridium difficile infection in near future. For instance, in January 2017, Pfizer announced phase II study of investigational clostridium difficile vaccine candidate: PF-06425090; for the prevention of C. difficile infection. This randomized phase II study was conducted to examine the safety, tolerability, and immunogenicity of the vaccine in healthy adults aged 65 to 85 years. In March 2017, Pfizer initiated the phase III study with around 16,000 volunteers.

Furthermore, in July 2016, Valneva SE announced the successful completion of its phase II clinical study for its prophylactic vaccine candidate VLA84 targeting on primary prevention of C. difficile infection (CDI).

Global Clostridium Vaccine Market Regional Insights

Among regions, North America is expected to hold a dominant position in the global clostridium vaccine market and is expected to account for the largest market share during the forecast period. This growth is owing to increased prevalence of Clostridium difficile in the U.S. coupled with growing awareness regarding the adoption of preventive measurement in Clostridium difficile infection in this region.

For instance, according to CDC, in 2011, healthcare-associated infections (HAIs) caused by C. difficile were estimated to cause around half a million infections in the U.S. and caused deaths of around 29,000 within 30 days of the initial diagnosis.

Global Clostridium Vaccine Market-Challenges

High cost required for late stage testing and increased risk related to failure of vaccine candidate during the clinical trial studies is expected to hinder the global clostridium vaccine market growth over the forecast period.

For instance, in December 2017, Sanofi terminated its phase III C. difficile clinical trial studies, due to the results of an interim trial analysis, which stated low probability of success with its C. difficile candidate. Moreover, discontinuation of Sanofi’s C. difficile vaccine program is expected to offer great future opportunity for Pfizer and Valneva to offer its vaccine to patients after getting the satisfactory regulatory approval in the future.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2359

Global Clostridium Vaccine Market-Key Players

Key players operating in the global clostridium vaccine market include Valneva SE and Pfizer, Inc.

Global Clostridium Vaccine Market Taxonomy:

The global clostridium vaccine market is segmented on the basis of vaccine and region

By Vaccine

• PF-06425090
• VLA84

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.